The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of Coronavirus disease in 2019 (COVID‐19). Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) ‐6, IL‐10 and TNF‐α. We describe a clinical series of eight patients treated with Sarilumab an IL‐6R inhibitor administered early in Covid‐19 pneumonia.